Abstract: The present invention relates to a novel pharmaceutical composition of Tamsulosin and Dutasteride and process of manufacture thereof. Specifically, the present invention relates to multiparticulate(s) of Tamsulosin and Dutasteride filled in capsule or/compressed in tablet dosage form and process of manufacture thereof.

Abstract: The present invention relates to a novel multiparticulate pharmaceutical composition for oral administration with a controlled dissolution rate. The composition comprises Tamsulosin hydrochloride in modified release form and Solifenacin succinate in mmediate release form, wherein the core comprises Tamsulosin hydrochloride and an outer immediate layer comprises Solifenacin succinate. According to the present invention, the instant formulation release the drug at predetermined rate and prevent dose dumping as well as improving the patient compliance.

Abstract: The present invention relates to solid composition of Tofacitinib and salt thereof, and process of manufacture thereof. The present invention relates to non-osmotic an extended release composition comprising Tofacitinib or salt thereof, mixture of polyethylene oxides along with one or more pharmaceutically acceptable excipient. The non-osmotic an extended release composition of Tofacitinib or salt thereof is used in the treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ulcerative Colitis.

Abstract: The present invention relates to extended release composition of Mirabegron and process of manufacture thereof. The extended release composition of mirabegron comprising non-polymeric hydrophobic excipient as release controlling agent along with one or more pharmaceutically acceptable excipient is used in the treatment of symptoms associated with overactive bladder.

Abstract: This invention discloses an orodispersible thin film for providing a substrate for printing of at least one Active ingredient on its surface that remains free from cavities after printing, method making the film, the substrate for the printing and a hydrophobic edible ink comprising at least one Active Ingredient for the printing. The Invention includes all films having orodispersibility property; including rectal, vaginal, ocular film and any other film meant for oral or transmucosal delivery. One or more of ingredient/s that make the substrate of this invention act as adsorbents and impart/s required roughness to the surface of the substrate. The ink does not crystallize on drying and remains stable at least for six months at 40° C. and 75% RH; and is printable using a Continuous Inkjet printer.

Abstract: The present invention relates to a novel pharmaceutical composition of Tamsulosin and Dutasteride and process of manufacture thereof. Specifically, the present invention relates to multiparticulate(s) of Tamsulosin and Dutasteride filled in capsule or/compressed in tablet dosage form and process of manufacture thereof.

Abstract: This invention comprises a method of transmucosal delivery of process of Vitamin B12 without the need of intrinsic factor comprising administering a solid composition comprising a Vitamin B12 and at least one bifunctional macromolecule with hydrophilic exterior and with hydrophobic pockets capable of pocketing Vitamin B12 material, illustrated by cyclodextrin, at least one permeation enhancer, illustrated by Isopropyl Myristate and at least one agent that is mucoadhessive as well as penetration enhancer, illustrated by chitosan. The solid composition of Vitamin B12 of claim 2 may comprise a lozenge, a candy, a wafer, a tablet, a patch, a film, a spray, a lip balm, or gum.